![]() |
市場調查報告書
商品編碼
1780320
顯微鏡市場規模及預測(2021-2031 年)、全球及區域成長機會分析報告涵蓋範圍:依技術、最終用戶及地理分類Microscope Market Size and Forecast 2021-2031, Global and Regional Growth Opportunity Analysis Report Coverage: By Technology, End User, and Geography |
預計顯微鏡市場規模將從2024年的26.5億美元增加到2031年的40.3億美元。預計2025-2031年期間的複合年成長率為6.20%。推動市場成長的主要因素包括科學研究和醫療保健應用的日益增多,以及研發資金的不斷增加。此外,在預測期內,顯微鏡中人工智慧和遠端技術的日益整合有望推動市場發展。然而,高昂的初始成本和維護成本是阻礙市場發展的因素之一。
人工智慧 (AI) 與遠端技術的整合正在徹底改變顯微鏡市場,推動成像、資料分析和可近性方面的進步。人工智慧顯微鏡系統提高了影像解讀的精確度、速度和深度,使研究人員和臨床醫生能夠更有效率地從複雜樣本中提取有意義的見解。人工智慧演算法可以自動識別和分類細胞,檢測組織樣本中的異常情況,並即時量化分子相互作用,從而顯著減少人為錯誤並加速診斷過程。基於數位和雲端技術的遠端顯微鏡技術是對人工智慧整合的補充,允許專家遠端進行高解析度成像和分析。這種能力在遠距醫療領域尤其具有變革性,遠距診斷可以為醫療資源匱乏或地理位置偏遠的人提供及時且準確的醫療服務。遠端顯微鏡的使用也支持協作研究,使全球各地的多位專家能夠同時即時查看和操作顯微影像,促進跨機構創新和知識共享。例如,蔡司的人工智慧數位顯微鏡平台將自動影像分析與基於雲端的資料共享相結合,使病理學家能夠以更高的精度審查幻燈片。同樣,徠卡顯微系統公司也開發了人工智慧輔助軟體工具,可與其顯微鏡無縫整合,從而比傳統的手動分析更快地檢測癌細胞和其他病理特徵。此外,全球範圍內人工智慧整合顯微鏡的推出正在增加。例如,2024 年 9 月,MedPrime Technologies 推出了 MICALYS,這是一個創新的人工智慧整合數位顯微鏡平台,旨在徹底改變印度的數位病理學。它提高了診斷精度,簡化了工作流程,並提高了整體生產力。這些系統不僅可以改善診斷結果,還可以最佳化臨床和研究實驗室的工作流程效率。因此,預計顯微鏡中人工智慧和遠端技術的日益整合將在未來幾年促進市場成長。
顯微鏡在醫學教育和培訓中至關重要,它使學生和專業人員能夠培養實踐技能,並加深對人體解剖學和病理學的理解。教育機構正在投資互動式數位顯微鏡平台,以實現虛擬顯微鏡和遠距學習。此外,顯微鏡在獸醫學、環境科學和農業研究中也發揮著至關重要的作用,可用於監測動物健康狀況、檢測環境污染物並提高作物產量。例如,電子顯微鏡廣泛應用於植物病理學,用於研究影響作物的病毒和真菌,從而促進抗病植物品種的培育。因此,研究和醫療保健應用範圍的不斷擴大,加上顯微鏡技術的進步,推動了顯微鏡市場的成長。
此外,政府、私人機構和組織正在向醫療保健、生物技術、奈米技術和材料科學等領域的科學研究和開發投入更多資源。資金的激增使研究機構和大學能夠採購最先進的顯微鏡設備。例如,美國國立衛生研究院 (NIH) 一直在增加預算,到 2025 年將超過 480 億美元。該預算的很大一部分用於支持嚴重依賴顯微成像技術的研究,從癌症生物學到傳染病研究。這些資金的湧入鼓勵實驗室從傳統顯微鏡升級到更先進的型號,例如共聚焦顯微鏡、電子顯微鏡和超解析度顯微鏡,這些顯微鏡可以提供更高的精度和更詳細的成像能力。
比較公司分析根據產品組合(產品滿意度、產品特性和可用性)、近期市場發展(併購、新產品發布和增強、投資和融資、獎勵、協議、合作和夥伴關係、認可和擴展)以及地理位置對體外肺模型市場進行評估和分類,以幫助更好地決策和了解競爭格局。該報告深入探討了全球體外肺模型市場主要供應商近期的重要發展和創新。主要市場參與者包括卡爾蔡司股份公司、布魯克公司、徠卡顯微系統公司、尼康公司、賽默飛世爾科技公司、奧林巴斯公司、ACCU-SCOPE、牛津儀器公司、Euromex Microscopen BV、Coxem 有限公司和日立高科技公司。
根據技術,顯微鏡市場細分為光學顯微鏡、電子顯微鏡、掃描探針顯微鏡和其他顯微鏡。光學顯微鏡在2024年佔據了顯微鏡市場的最大佔有率,預計在2025年至2031年期間將實現顯著的複合年成長率。
就最終用戶而言,顯微鏡市場細分為學術機構和研究機構、製藥和生物製藥公司、診斷中心等。製藥和生物製藥公司在2024年佔據了顯微鏡市場的最大佔有率,預計在2025-2031年期間將實現顯著的複合年成長率。大學、學院和專門的研究中心廣泛使用顯微鏡進行生物學、化學、材料科學、奈米技術等領域的教學、基礎研究和實驗研究。持續的資金和資助促進了科學知識的累積和創新。學術環境中的顯微鏡種類繁多,從教室使用的基本光學模型到尖端研究實驗室使用的複雜電子顯微鏡和掃描探針顯微鏡。光學顯微鏡仍然是最常用的教學工具,使學生能夠探索細胞結構、微生物和組織樣本。例如,數位光學顯微鏡擴大被整合到課程中,以增強互動式學習體驗。同時,研究機構經常投資於透射電子顯微鏡 (TEM)、掃描電子顯微鏡 (SEM)、原子力顯微鏡 (AFM) 和共聚焦顯微鏡等高階技術,以便在微觀和奈米尺度上進行詳細的結構、化學和物理分析。此外,政府和私人組織持續撥出大量預算來支援科學基礎設施,推動先進顯微鏡系統的升級和採購。例如,美國國立衛生研究院 (NIH) 和歐洲研究理事會 (ERC) 等機構積極資助顯微鏡相關項目,為獲取最先進設備提供便利。
體外肺模型市場的公司採用各種有機和無機成長策略。有機成長策略主要包括產品發布和產品批准。市場上常見的無機成長策略包括收購、合作和夥伴關係。這些成長策略使市場參與者能夠拓展業務,增強地域影響力,並促進整體市場成長。此外,收購和夥伴關係等策略有助於鞏固客戶群並擴展產品組合。以下列出了體外肺模型市場主要參與者的一些重要進展。
2024 年 10 月,蔡司推出了新款 ZEISS Crossbeam 550 Samplefab,這是一款聚焦離子束掃描電子顯微鏡 (FIB-SEM),專為全自動製備透射電子顯微鏡 (TEM) 樣品而最佳化。
2024年6月,徠卡顯微系統公司推出了神經外科手術的ARveo 8數位視覺化顯微鏡的升級版。 ARveo 8透過應用3D視圖和擴增實境螢光技術,增強了手術視覺化效果。
The microscope market size is projected to reach US$ 4.03 billion by 2031 from US$ 2.65 billion in 2024. The market is estimated to register a CAGR of 6.20% during 2025-2031. Major factors driving the market growth include an increasing applications of research and healthcare, and the growing funding in research and development. Further, increasing integration of AI and remote technologies in the microscope is likely to boost the market during the forecast period. However, high initial and maintenance costs are among the market deterrents.
The integration of Artificial Intelligence (AI) and remote technologies is revolutionizing the microscope market leading to advancements in imaging, data analysis, and accessibility. AI-powered microscopy systems enhance the precision, speed, and depth of image interpretation, enabling researchers and clinicians to extract meaningful insights from complex samples with greater efficiency. AI algorithms can automatically identify and classify cells, detect abnormalities in tissue samples, and quantify molecular interactions in real time, which significantly reduces human error and accelerates diagnostic processes. Remote microscopy, enabled by digital and cloud technologies, complements AI integration by allowing specialists to conduct high-resolution imaging and analysis remotely. This capability is particularly transformative in telemedicine, where remote diagnostics can provide timely and accurate healthcare services to underserved or geographically isolated populations. The use of remote microscopy also supports collaborative research by enabling multiple experts across the globe to simultaneously view and manipulate microscopic images in real time, fostering cross-institutional innovation and knowledge sharing. For instance, Zeiss's AI-driven digital microscopy platform combines automated image analysis with cloud-based data sharing, allowing pathologists to review slides with enhanced accuracy. Similarly, Leica Microsystems has developed AI-assisted software tools that integrate seamlessly with their microscopes to detect cancer cells and other pathological features more rapidly than traditional manual analysis. Moreover, the launch of AI-integrated microscopes is increasing across the world. For instance, in September 2024, MedPrime Technologies launched MICALYS, which is an innovative AI-integrated digital microscopy platform that is set to revolutionize digital pathology in India. It elevates diagnostic precision, streamlines workflows, and boosts overall productivity. These systems not only improve diagnostic outcomes but also optimize workflow efficiencies in clinical and research laboratories. Therefore, increasing integration of AI and remote technologies in the microscope is expected to contribute the market growth in the coming years.
Microscopy is critical in medical education and training, enabling students and professionals to develop practical skills and a deeper understanding of human anatomy and pathology. Educational institutions are investing in interactive and digital microscopy platforms that allow virtual microscopy and remote learning. Moreover, microscopes are crucial in veterinary medicine, environmental science, and agricultural research to monitor animal health, detect environmental contaminants, and improve crop yields. For instance, electron microscopy is widely used in plant pathology to study viruses and fungi affecting crops, facilitating the development of disease-resistant plant varieties. Therefore, the expanding scope of research and healthcare applications, coupled with technological advancements in microscopy, drives the growth of the microscope market.
Moreover, governments, private institutions, and organizations are allocating more resources toward scientific research and development in healthcare, biotechnology, nanotechnology, and materials science, among others. This surge in funding enables research institutions and universities to procure state-of-the-art microscopy equipment. For instance, the National Institutes of Health (NIH) in the US has consistently increased its budget, reaching over US$ 48 billion in 2025. A significant portion of this budget supports research that relies heavily on microscopic imaging technologies, from cancer biology to infectious disease studies. This influx of funds encourages laboratories to upgrade from conventional microscopes to advanced models such as confocal, electron, and super-resolution microscopes that offer higher precision and more detailed imaging capabilities
The comparative company analysis evaluates and categorizes the in vitro lung models market based on product portfolio (product satisfaction, product features, and availability), recent market developments (merger & acquisition, new product launch & enhancement, investment & funding, award, agreement, collaboration, & partnership, recognition, and expansion), and geographic presence that aids better decision-making and understanding of the competitive landscape. The report profoundly explores the recent significant developments and innovations by the leading vendors in the global in vitro lung models market. The key market players are CARL ZEISS AG; Bruker Corporation; Leica Microsystems; Nikon Corporation; Thermo Fischer Scientific Inc.; Olympus Corporation; ACCU-SCOPE; Oxford Instruments Plc; Euromex Microscopen BV; Coxem Co.,Ltd; and Hitachi High-Tech Corp.
Based on technology, the microscope market is segmented into optical microscope, electron microscope, scanning probe microscope, and others. The optical microscope segment held the largest share of the microscope market in 2024, and it is expected to register a significant CAGR during 2025-2031.
In terms of end user, the microscope market is segmented into academics and research institutes, pharmaceuticals and biopharmaceutical companies, diagnostic centers, and others. The pharmaceuticals and biopharmaceutical companies segment held the largest share of the microscope market in 2024, and it is expected to register a significant CAGR during 2025-2031. Universities, colleges, and dedicated research centers utilize microscopes extensively for education, fundamental research, and experimental studies in biology, chemistry, materials science, nanotechnology, and others. Continuous funding and grants enhance scientific knowledge and innovations. Microscopes in academic settings range from basic optical models used in classrooms to sophisticated electron and scanning probe microscopes employed in cutting-edge research labs. Optical microscopes remain the most common tool for teaching purposes, enabling students to explore cell structures, microorganisms, and tissue samples. For instance, digital optical microscopes are increasingly integrated into curricula to enhance interactive learning experiences. Meanwhile, research institutes often invest in high-end technologies such as transmission electron microscopes (TEM), scanning electron microscopes (SEM), atomic force microscopes (AFM), and confocal microscopes to conduct detailed structural, chemical, and physical analyses at the micro and nanoscale. Additionally, governments and private organizations continue to allocate significant budgets to support scientific infrastructure, driving upgrades and purchases of advanced microscopy systems. For example, initiatives such as the US National Institutes of Health (NIH) and the European Research Council (ERC) actively fund microscopy-related projects, facilitating access to state-of-the-art equipment.
Various organic and inorganic strategies are adopted by companies operating in the in vitro lung models market. The organic strategies mainly include product launches and product approvals. Inorganic growth strategies witnessed in the market are acquisitions, collaboration, and partnerships. These growth strategies allow the market players to expand their businesses and enhance their geographic presence, along with contributing to the overall market growth. Furthermore, strategies such as acquisitions and partnerships helped strengthen their customer base and extend their product portfolios. A few of the significant developments by key players in the in vitro lung models market are listed below.
In October 2024, ZEISS launched new ZEISS Crossbeam 550 Samplefab, a focused ion beam scanning electron microscope (FIB-SEM) optimized for fully automated preparation of transmission electron microscopy (TEM) samples.
In June 2024, Leica Microsystems introduced an evolved version of its ARveo 8 digital visualization microscope for neurosurgery. The ARveo 8 enhances surgical visualization by applying a 3D view and augmented reality fluorescence.